U031 JAAD Game Changers
DESCRIPTION
JAAD Game Changers are a selection of landmark articles that have changed the way dermatology is practiced. This forum will consist of short presentations by Game Changer article authors followed by a 15-minute interchange with the audience to ask the authors questions about their ground-breaking work. The selected top nine Game Changers over the last 10 years of JAAD will be presented. At the end of this session, the audience will use an Audience Response System to vote for "JAAD Game Changer of the Year." This activity has been approved by the American Board of Dermatology (ABD) for up to 10 Continuous Certification Program (CCP) Component 2 Self-Assessment points. For more information about CCP, please visit the ABD website at www.abderm.org.
LEARNING OBJECTIVES
Summarize selected seminal JAAD publications spanning a 10-year period.
Discuss the publications focusing on application of knowledge to the diagnosis, management, and treatment of dermatologic disease.
Promote academic interchange with the authors of selected publications to improve retention of information.
SCHEDULE
7:30 AM
Introduction
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD
7:32 AM
The clinical utility of laboratory monitoring during isotretinoin therapy for acne and changes to monitoring practices over time
John S. Barbieri, MD, MBA, FAAD
7:36 AM
Etanercept therapy for toxic epidermal necrolysis
Andrea Paradisi
7:40 AM
Clinical and dermoscopic features of cutaneous BAP1-inactivated melanocytic tumors: Results of a multicenter case-control study by the International Dermoscopy Society
Oriol Yelamos, MD, IFAAD
7:44 AM
To test or not to test? An updated evidence-based assessment of the value of screening and monitoring tests when using systemic biologic agents to treat psoriasis and psoriatic arthritis
William Huang, MD, MPH, FAAD
7:48 AM
Risk of new-onset inflammatory bowel disease among patients with acne vulgaris exposed to isotretinoin
Amit Garg, MD, FAAD
7:52 AM
Variability in mitotic figures in serial sections of thin melanomas
Stevan Knezevich
7:56 AM
The use of oral antibiotics before isotretinoin therapy in patients with acne
Arielle Rachel Nagler, MD, FAAD
8:00 AM
Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma
Eunice Chavez Del Rosario, MS, MD, FAAD
8:04 AM
Patient quality of life fluctuates before and after Mohs micrographic surgery: A longitudinal assessment of the patient experience
Joseph Sobanko, MD, FAAD
8:08 AM
Interactive audience question & answer session with all GC authors
8:27 AM
Selection of JAAD Game Changer of the Year via ARS/Closing remarks
Wendi E. Wohltmann, MD, FAAD, Eden Louise Pappo Lake, MD, FAAD
DIRECTOR
Wendi E. Wohltmann, MD, FAAD
CO-DIRECTOR
Eden Louise Pappo Lake, MD, FAAD
SPEAKERS
John S. Barbieri, MD, MBA, FAAD
Eunice Chavez Del Rosario, MS, MD, FAAD
Amit Garg, MD, FAAD
William Huang, MD, MPH, FAAD
Stevan Knezevich
Arielle Rachel Nagler, MD, FAAD
Andrea Paradisi
Joseph Sobanko, MD, FAAD
Oriol Yelamos, MD, IFAAD
HANDOUTS
DISCLOSURES
John S. Barbieri, MD, MBA, FAAD
Honeydew Care – Consultant (1099 relationship)(Fees); National Institutes of Health – Other(Grants/Research Funding); National Psoriasis Foundation – Other(Grants/Research Funding);
Eunice Chavez Del Rosario, MS, MD, FAAD
No financial relationships exist with ineligible companies.
Amit Garg, MD, FAAD
AbbVie – Advisory Board(Honoraria); Boehringer Ingelheim – Advisory Board(Honoraria); Bristol-Myers Squibb – Advisory Board(Honoraria); Incyte Corporation – Advisory Board(Honoraria); Insmed Incorporated – Consultant (1099 relationship)(Honoraria); Janssen Pharmaceuticals, Inc – Advisory Board(Honoraria); Novartis – Consultant(Honoraria); Pfizer Inc. – Investigator(Grants/Research Funding); Sanofi – Data Safety Monitoring Board(Fees); UCB – Consultant(Honoraria); Union Therapeutics – Advisory Board(Honoraria);
William Huang, MD, MPH, FAAD
Dermatology Foundation – Advisory Board(No Compensation Received); Medical Dermatology Society – Board of Directors(No Compensation Received);
Stevan Knezevich
No financial relationships exist with ineligible companies.
Arielle Rachel Nagler, MD, FAAD
ClearMD – Consultant(No Compensation Received), Consultant(Stock);
Eden Louise Pappo Lake, MD, FAAD
No financial relationships exist with ineligible companies.
Andrea Paradisi
No financial relationships exist with ineligible companies.
Joseph Sobanko, MD, FAAD
No financial relationships exist with ineligible companies.
Wendi E. Wohltmann, MD, FAAD
No financial relationships exist with ineligible companies.
Oriol Yelamos, MD, IFAAD
Almirall – Consultant(Honoraria), Investigator(Fees), Speaker(Honoraria); ISDIN – Speaker(Honoraria); ISIS Pharma – Consultant(Honoraria), Speaker(Honoraria); Leo Pharma A/S – Advisory Board(Honoraria); Leo Pharma Inc – Speaker(Honoraria); NAOS – Consultant (1099 relationship)(Honoraria); Philogen S.p.A. – Investigator(Fees); Viatris Inc. – Speaker/Faculty Education(Honoraria);